Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 11, 2015, Pages E1288-E1296

  Faber, Anthony C ^a,b,d   Farago, Anna F ^a,b,c   Costa, Carlotta ^a,b   Dastur, Anahita ^a,b   Gomez Caraballo, Maria ^a,b   Robbins, Rebecca ^c   Wagner, Bethany L ^c   Rideout, William M ^c   Jakubik, Charles T ^a,b   Ham, Jungoh ^a,b   Edelman, Elena J ^a,b   Ebi, Hiromichi ^a,b,e   Yeo, Alan T ^a,b   Hata, Aaron N ^a,b   Song, Youngchul ^a,b   Patel, Neha U ^d   March, Ryan J ^a,b   Tam, Ah Ting ^a,b   Milano, Randy J ^a,b   Boisvert, Jessica L ^a,b   Hicks, Mark A ^d   Elmiligy, Sarah ^c   Malstrom, Scott E ^c   Rivera, Miguel N ^a   Harada, Hisashi ^d   Windle, Brad E ^d   Ramaswamy, Sridhar ^a,b   Benes, Cyril H ^a,b   Jacks, Tyler ^c   Engelman, Jeffrey A ^a,b   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^e KANAZAWA UNIVERSITY   (Japan)

Author keywords

Apoptosis; BH3 mimetics; BIM; Small cell lung cancer; Targeted therapies

Indexed keywords

AZD 8055; BIM PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; NAVITOCLAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; RETINOBLASTOMA PROTEIN; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; BCL-2-LIKE PROTEIN 11; MCL1 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MEMBRANE PROTEIN; MORPHOLINE DERIVATIVE; MULTIPROTEIN COMPLEX; ONCOPROTEIN; SULFONAMIDE; TARGET OF RAPAMYCIN KINASE; TOR COMPLEX 2;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RESISTANCE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; GENE EXPRESSION; GENETICALLY ENGINEERED MOUSE STRAIN; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SMALL CELL LUNG CANCER; SOLID TUMOR; TREATMENT DURATION; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; GENETIC ENGINEERING; IC50; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; REMISSION; SMALL CELL LUNG CARCINOMA; TUMOR CELL LINE;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC ENGINEERING; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MEMBRANE PROTEINS; MICE; MORPHOLINES; MULTIPROTEIN COMPLEXES; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS; REMISSION INDUCTION; SMALL CELL LUNG CARCINOMA; SULFONAMIDES; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925337149     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1411848112     Document Type: Article

References (45)

1. Faber AC, Ebi H, Costa C, Engelman JA (2012) Apoptosis in targeted therapy responses: The role of BIM. Adv Pharmacol 65:519-542.
2. Faber AC, et al. (2011) BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors. Cancer Discov 1(4):352-365.
3. Faber AC, et al. (2009) Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 106(46):19503-19508.
4. Costa C, et al. (2014) The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 20(7):2001-2010.
5. Tse C, et al. (2008) ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68(9):3421-3428.
6. Del Gaizo Moore V, et al. (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117(1):112-121.
7. Faber AC, et al. (2014) mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1. Cancer Discov 4(1):42-52.
8. Sale MJ, Cook SJ (2013) The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. Biochem J 450(2):285-294.
9. Chen S, Dai Y, Harada H, Dent P, Grant S (2007) Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67(2):782-791.
10. Lin X, et al. (2007) 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26(27):3972-3979.
11. Roberts AW, et al. (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30(5):488-496.
12. Al-Harbi S, et al. (2011) An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737. Blood 118(13):3579-3590.
13. Garnett MJ, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
14. Adams JM, et al. (2005) Subversion of the Bcl-2 life/death switch in cancer development and therapy. Cold Spring Harb Symp Quant Biol 70:469-477.
15. van Delft MF, et al. (2006) The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10(5):389-399.
16. Mason KD, et al. (2008) In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 105(46):17961-17966.
17. Nguyen M, et al. (2007) Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104(49):19512-19517.
18. Rodriguez E, Lilenbaum RC (2010) Small cell lung cancer: Past, present, and future. Curr Oncol Rep 12(5):327-334.
19. Shoemaker AR, et al. (2008) Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res 14(11):3268-3277.
20. Sartorius UA, Krammer PH (2002) Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97(5):584-592.
21. Hann CL, et al. (2008) Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res 68(7):2321-2328.
22. Gandhi L, et al. (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909-916.
23. Mason KD, et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128(6):1173-1186.
24. Rudin CM, et al. (2012) Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18(11):3163-3169.
25. McCoy F, et al. (2010) Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. Cell Death Dis 1:e108.
26. Hwang JJ, et al. (2010) Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-BCL-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin Cancer Res 16(15):4038-4045.
27. Paik PK, et al. (2011) A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. Lung Cancer 74(3):481-485.
28. Wendel HG, et al. (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21(24):3232-3237.
29. Schatz JH, et al. (2011) Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J Exp Med 208(9):1799-1807.
30. Mills JR, et al. (2008) mTORC1 promotes survival through translational control of Mcl-1.Proc Natl Acad Sci USA 105(31):10853-10858.
31. Hsieh AC, et al. (2010) Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 17(3):249-261.
32. Chresta CM, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res 70(1):288-298.
33. Choo AY, Yoon SO, Kim SG, Roux PP, Blenis J (2008) Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc Natl Acad Sci USA 105(45):17414-17419.
34. Cope CL, et al. (2014) Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation. J Cell Sci 127(Pt 4):788-800.
35. Gardner EE, et al. (2014) Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res 74(10):2846-2856.
36. Meuwissen R, et al. (2003) Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 4(3):181-189.
37. Sutherland KD, et al. (2011) Cell of origin of small cell lung cancer: Inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 19(6):754-764.
38. Dooley AL, et al. (2011) Nuclear factor I/B is an oncogene in small cell lung cancer. Genes Dev 25(14):1470-1475.
39. McFadden DG, et al. (2014) Genetic and clonal dissection of murine small cell lung carcinoma progression by genome sequencing. Cell 156(6):1298-1311.
40. Peifer M, et al. (2012) Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet 44(10):1104-1110.
41. Rudin CM, et al. (2012) Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet 44(10):1111-1116.
42. Hanna N, et al. (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24(13):2038-2043.
43. Singh M, et al. (2012) Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models. J Pathol 227(4):417-430.
44. Rossi A, et al. (2012) Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 30(14):1692-1698.
45. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.